Autolus Therapeutics plc
AUTL · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $21 | $21 | $9 | $0 |
| % Growth | 1.3% | 132.9% | 30,872.4% | – |
| Cost of Goods Sold | $29 | $24 | $18 | $138 |
| Gross Profit | -$7 | -$4 | -$9 | -$138 |
| % Margin | -35.1% | -16.8% | -99.9% | -476,810.3% |
| R&D Expenses | $28 | $27 | $27 | $51 |
| G&A Expenses | $36 | $30 | $30 | $67 |
| SG&A Expenses | $36 | $30 | $30 | $42 |
| Sales & Mktg Exp. | $0 | $0 | $0 | -$25 |
| Other Operating Expenses | $0 | $0 | $0 | $10 |
| Operating Expenses | $64 | $58 | $56 | $103 |
| Operating Income | -$72 | -$61 | -$65 | -$241 |
| % Margin | -337.9% | -292.6% | -726.3% | -832,503.4% |
| Other Income/Exp. Net | -$7 | $14 | -$3 | $215 |
| Pre-Tax Income | -$79 | -$48 | -$68 | -$26 |
| Tax Expense | $1 | $0 | $2 | $1 |
| Net Income | -$79 | -$48 | -$70 | -$28 |
| % Margin | -373.3% | -229% | -781.1% | -95,193.1% |
| EPS | -0.3 | -0.18 | -0.26 | -0.1 |
| % Growth | -66.7% | 30.8% | -160% | – |
| EPS Diluted | -0.3 | -0.18 | -0.26 | -0.1 |
| Weighted Avg Shares Out | 266 | 266 | 266 | 266 |
| Weighted Avg Shares Out Dil | 266 | 266 | 266 | 266 |
| Supplemental Information | – | – | – | – |
| Interest Income | $4 | $12 | $6 | $7 |
| Interest Expense | $11 | $0 | $10 | -$31 |
| Depreciation & Amortization | $3 | $4 | $2 | $2 |
| EBITDA | -$65 | -$57 | -$56 | -$74 |
| % Margin | -305.3% | -272% | -618.1% | -254,437.9% |